David A. Ellis

A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity

A. H. Underwood, J. C. EMMETT, David A. Ellis et al. · Nature · 1986 · 131 citations

Pharmacy, Endocrinology, Pharmacology +11

Discovery of Clinical Candidate 4-[2-(5-Amino-1<i>H</i>-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-<i>N</i>-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na_V1.7

Nigel A. Swain, D. V. Batchelor, Serge Beaudoin et al. · Journal of Medicinal Chemistry · 2017 · 83 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

IMMUNOSUPPRESSIVE EFFECTS OF AN INTERFERON PREPARATION IN VIVO

Martin Hirsch, David A. Ellis, Paul H. Black et al. · Transplantation · 1974 · 66 citations

Life Sciences, Immunology, Clinical Immunology +3

Leukemia Virus Activation during Homograft Rejection

Martin Hirsch, David A. Ellis, Paul H. Black et al. · Science · 1973 · 60 citations

Life Sciences, Immunology, Microbiology +14

An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of <i>N</i>-{(1<i>S</i>)-1-(3-Fluorophenyl)-3-[(3-<i>endo</i>)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)

Paul A. Stupple, David V. Batchelor, Martin Corless et al. · Journal of Medicinal Chemistry · 2010 · 40 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17